MIT-Takeda program launches
Research projects will harness the power of artificial intelligence to positively impact human health.
In February, researchers from MIT and Takeda Pharmaceuticals joined together to celebrate the official launch of the MIT-Takeda Program. The MIT-Takeda Program aims to fuel the development and application of artificial intelligence (AI) capabilities to benefit human health and drug development. Centered within the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic), the program brings together the MIT School of Engineering and Takeda Pharmaceuticals, to combine knowledge and address challenges of mutual interest.
Following a competitive proposal process, nine inaugural research projects were selected. The program’s flagship research projects include principal investigators from departments and labs spanning the School of Engineering and the Institute. Research includes diagnosis of diseases, prediction of treatment response, development of novel biomarkers, process control and improvement, drug discovery, and clinical trial optimization.
“We were truly impressed by the creativity and breadth of the proposals we received,” says Anantha P. Chandrakasan, dean of the School of Engineering, Vannevar Bush Professor of Electrical Engineering and Computer Science, and co-chair of the MIT-Takeda Program Steering Committee.
